Public Reporting of Outcomes
At the Cancer Centers of Sharp HealthCare, we are committed to sharing the outcomes of our efforts to continuously evaluate and improve the quality of care we provide. Through feedback from our patients, our physicians and comparison to national cancer benchmarks and publications, we continuously identify and act upon opportunities for improvement.
Cancer Program Practice Profile Reports (CP3R)*
Using national clinical trials and extensive research analysis, specific standards for diagnosis, staging and treatment have been established. In conjunction with these care standards, leading organizations — such as the American College of Surgeons, Commission on Cancer — have developed measures to serve as benchmarks for quality cancer care. At Sharp, we use these measures to routinely assess our performance and drive care improvements to benefit our patients and their care outcomes.
The following information details our performance across Sharp HealthCare for breast and colorectal quality measures for 2016.
Estimated Performance Report for 2016
Measure: Radiation is administered within one year of diagnosis for women under the age of 70 receiving breast conservation surgery for breast cancer.
- Benchmark: 90.0%
- Sharp HealthCare: 92.7%
Measure: Tamoxifen or third generation aromatase inhibitor is recommended or administered within one year of diagnosis for women with AJCC T1c or stage 1B-III hormone receptor positive breast cancer.
- Benchmark: 90.0%
- Sharp HealthCare: 92.3%
Measure: Radiation therapy is recommended or administered following any mastectomy within one year of diagnosis of breast cancer for women with >4 positive regional lymph nodes.
- Benchmark: 90.0%
- Sharp HealthCare: 95.5%
Measure: Image or palpation-guided needle biopsy to the primary site is performed to establish diagnosis of breast cancer.
- Benchmark: 80.0%
- Sharp HealthCare: 97.4%
Measure: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.
- Benchmark: 85.0%
- Sharp HealthCare: 91.7%
Measure: Preoperative chemotherapy and radiation are administered for clinical AJCC T3N0, T4N0 or Stage III; postoperative chemotherapy and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0 or Stage III; or treatment is recommended for patients under the age of 80 receiving resection for rectal cancer.
- Benchmark: 85%
- Sharp HealthCare: 84.6%
*CP3R offers local providers comparative information to assess adherence to and consideration of standard care therapies for major cancers. This reporting tool provides a platform from which to promote continuous practice improvement to improve quality of patient care at the local level and also permits hospitals to compare their care for these patients relative to that of other providers.
Choose the best doctor in San Diego for you.
View doctors specializing in oncology in San Diego.
"I strive to offer excellent cancer care — either in the office, in the hospital or at home."
"My goal is to have my patients feel the warmth of my true concern for their health."
"The Sharp Experience means patient-centered care combined with state-of-the-art technology."
"The Sharp Experience is a whole-patient approach to care. Sharp provides nutrition services, patient navigation, support groups, counseling and high-quality treatment."
"I am a firm believer in a holistic, integrative approach to cancer treatment and prevention."
"I am dedicated to providing compassionate and exceptional cancer care to my patients and caring for the whole family"
"I provide sensitive, comprehensive care for patients with cancer and blood disorders."
"My mission is to provide compassionate and courteous care to all of my patients."
"My goal is to provide you with information to help guide you through this challenging time."